Vitamin D Deficiency Affects Cognition in Multiple Sclerosis
May 9, 2017
Hepatitis C has been eradicated in 20 patients who received infected kidney transplants
May 10, 2017
Show all

Multiple Sclerosis Relapse Burden Is Underappreciated, Study Contends

Relapses in multiple sclerosis might be a bigger problem than previously thought.

The burden of moderate-to-severe relapses in multiple sclerosis (MS) patients is underappreciated, according to a study sponsored by the pharmaceutical company Mallinckrodt.

Researchers discussed the findings at the American Academy of Neurology’s 69th annual meeting in Boston, April 22-28. The title of the presentation was “The Economic Burden Of Moderate-To-Severe Multiple Sclerosis Relapse In The United States: Findings From A Systematic Literature Review.”

The research team reviewed 24 scientific studies on the economic burden of MS relapses. Most did not address relapse severity, but those that did showed that the cost and impact of MS relapses increases with the severity of the episodes.

A study in 2003 put the three-month cost of a moderate-intensity relapse at $1,847 and a high-intensity one at $12,870. In 2016, those costs would be equivalent to $3,092 and $21,544.

Read full article: Multiple Sclerosis Relapse Burden Is Underappreciated, Study Contends

Read Full Article: Multiple Sclerosis Relapse Burden Is Underappreciated, Study Contends

The health and medical information on our website is not intended to take the place of advice or treatment from health care professionals. It is also not intended to substitute for the users’ relationships with their own health care/pharmaceutical providers.

Comments are closed.